The Opioid-Induced Constipation (OIC) Treatment Market is estimated to be valued at USD 2.9 billion in 2025 and is projected to reach USD 4.5 billion by 2035, registering a compound annual growth rate (CAGR) of 4.6% over the forecast period.
-treatment-market-market-value-analysis.webp "Opioid Induced Constipation (oic) Treatment Market Market Value Analysis")
| Metric | Value |
|---|---|
| Opioid-Induced Constipation (OIC) Treatment Market Estimated Value in (2025 E) | USD 2.9 billion |
| Opioid-Induced Constipation (OIC) Treatment Market Forecast Value in (2035 F) | USD 4.5 billion |
| Forecast CAGR (2025 to 2035) | 4.6% |
The opioid-induced constipation (OIC) treatment market is experiencing steady growth, driven by the rising prevalence of chronic pain conditions requiring long-term opioid therapy and the associated gastrointestinal side effects. As opioid prescriptions continue to increase for cancer, palliative care, and chronic pain management, demand for effective and safe OIC treatments is expanding significantly. Patient awareness regarding the availability of specialized therapies is improving, supported by physician education initiatives and broader access to prescription treatments.
Regulatory approvals of novel therapies and the inclusion of OIC-specific medications in treatment guidelines are reinforcing adoption. Oral formulations and targeted therapies that minimize systemic opioid interference are gaining attention, creating a favorable shift away from traditional laxatives toward mechanism-based solutions.
Pharmaceutical companies are also investing in expanding therapeutic pipelines and conducting post-marketing studies to demonstrate safety and efficacy in larger populations As healthcare systems prioritize patient quality of life, the OIC treatment market is expected to maintain its growth trajectory, with continued emphasis on personalized approaches and advanced therapeutic classes.
The opioid-induced constipation (oic) treatment market is segmented by active ingredient, method of administration, drug class, distribution channel, and geographic regions. By active ingredient, opioid-induced constipation (oic) treatment market is divided into Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, and Others (Osmotic laxatives, Emollient or lubricant cathartics, Bulk cathartics, Stimulant cathartics, Prostaglandins or prokinetic drugs). In terms of method of administration, opioid-induced constipation (oic) treatment market is classified into Oral and Parenteral (Subcutaneous Injection). Based on drug class, opioid-induced constipation (oic) treatment market is segmented into Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA), Non-selective opioid antagonist, μ-Opioid antagonist, and Locally Acting Chloride Channel Activator (LACCA). By distribution channel, opioid-induced constipation (oic) treatment market is segmented into Hospital Pharmacies, Drug store, and Independent Pharmacies. Regionally, the opioid-induced constipation (oic) treatment industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
-treatment-market-analysis-by-active-ingredient.webp "Opioid Induced Constipation (oic) Treatment Market Analysis By Active Ingredient")
The naloxegol active ingredient segment is projected to hold 36.7% of the opioid-induced constipation treatment market revenue share in 2025, making it the leading drug ingredient. Its dominance is supported by its effectiveness as a targeted peripherally acting μ-opioid receptor antagonist that relieves constipation without affecting central analgesic effects of opioids. The segment’s growth is reinforced by its favorable safety profile, oral dosing convenience, and demonstrated efficacy in both cancer and non-cancer pain patients.
Clinical trial evidence and real-world studies have validated naloxegol’s ability to improve bowel function with sustained tolerability, driving physician confidence and patient acceptance. Broad availability across multiple regions and established reimbursement support have also contributed to its widespread use.
Ongoing research exploring combination regimens and long-term safety further enhances its clinical positioning As patient demand for reliable and mechanism-based therapies grows, naloxegol is expected to remain the leading active ingredient in the OIC treatment market, supported by its proven therapeutic outcomes and expanding global adoption.
-treatment-market-analysis-by-method-of-administration.webp "Opioid Induced Constipation (oic) Treatment Market Analysis By Method Of Administration")
The oral method of administration segment is anticipated to account for 61.3% of the opioid-induced constipation treatment market revenue share in 2025, making it the dominant delivery route. Its leadership is primarily driven by patient preference for non-invasive and convenient treatment options that can be integrated seamlessly into daily routines. Oral formulations provide consistent dosing and adherence benefits, which are particularly important in chronic opioid users requiring long-term constipation management.
Pharmaceutical companies have focused extensively on developing oral versions of PAMORAs and other targeted agents, ensuring broad accessibility and market penetration. The segment’s growth is further supported by favorable physician prescribing patterns, as oral options are often easier to initiate compared to injectable or rectal alternatives.
Improved bioavailability and controlled-release technologies are enhancing therapeutic effectiveness, reinforcing patient compliance and clinical outcomes With healthcare providers emphasizing ease of use and long-term safety, the oral method of administration is expected to continue holding the largest share in the OIC treatment market, supported by strong acceptance among both patients and prescribers.
-treatment-market-analysis-by-drug-class.webp "Opioid Induced Constipation (oic) Treatment Market Analysis By Drug Class")
The peripherally-restricted μ-opioid receptor antagonist (PAMORA) drug class segment is expected to represent 29.6% of the opioid-induced constipation treatment market revenue share in 2025, positioning it as the leading therapeutic class. Its dominance is being driven by the ability to specifically target opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby preserving pain relief benefits while mitigating constipation.
The segment has gained significant traction due to robust clinical evidence demonstrating improved bowel function and quality of life compared to traditional laxatives. Increasing regulatory approvals, expanding product availability, and growing prescriber confidence are reinforcing the adoption of PAMORAs in both hospital and outpatient settings.
The class also benefits from strong market presence of leading agents such as naloxegol, naldemedine, and methylnaltrexone, which have established safety profiles and proven efficacy As treatment guidelines evolve to recommend mechanism-specific therapies for OIC, PAMORAs are expected to maintain their leadership, supported by rising physician preference and growing demand for advanced, targeted solutions.
Opioids are a class of medications that are regularly endorsed for their pain relieving, or pain-killing, properties it is chronic and non-cancer pain. A typical symptom connected with the utilization of these medications are that they decrease the gastrointestinal tract's motility, making solid discharges and making patients strain.
In addition, prolonged utilization of opioids can prompt the harm of sensory system that causes body cells to quit creating endogenous opioids, for example, endorphins. There is high risk of constipation in adults since they have poor diet, poor fluid intake and immobility.
The typical symptoms for opioid-induced constipation are feeling lethargic, hard and dry stools, distention and bulged abdomen, painful defecation and loss of appetite. The opioid-induced constipation (OIC) treatment market is an exceptionally alluring and promising market because of the expanding base of opioid-induced constipation OIC sufferers.
Raising base of the illegal medication users and delayed utilization of opioids in the treatment of chronic pain are the essential elements energizing the development of the opioid- induced constipation (OIC) treatment business sector. In addition, expanded mindfulness among patients and doctors for utilizing non-purgative medicine choices to treat opioid induced constipation would promote drive the development of the OIC treatment market sooner rather than later.
In addition, it has been assessed that the undiscovered market for successful, advantageous and safe medication treatment in OIC drug is profoundly broad and developing. However, lack of awareness about opioid-induced constipation in patients, absence of mindfulness with respect to the forthcoming treatment innovation, high costs of novel pharmaceuticals and unfavorable reimbursement guidelines by medical coverage organizations are probably the most prevailing limit for the opioid- induced constipation treatment market.
With expanding base of opioid-induced constipation (OIC) sufferers, the opioid-induced constipation (OIC) treatment market is expected to have tremendous growth during the forecast period (2025-2026). The latest trend in the opioid-induced constipation market is development of novel and effective treatment technology by incurring nominal expenses in research and development (R&D).
Introducing convenient dosing, peripherally restricted μ-opioid receptor antagonist (PAMORA) target main cause of opioid- induced constipation (OIC) thiswill drive the opioid- induced constipation (OIC) treatment market.
North America is the main market for opioid induced constipation treatment because of the expanding base of OIC sufferers and illegal medication users. It is then followed by Europe because of high incidence of opioid-induced constipation OIC for chronic pain. Besides that, Latin America and South East-Asia area are some of potential areas where presentation of successful opioid-induced constipation treatments may help up the general income of a specific pharmaceutical organization, because of the expanding base of OIC sufferers.
The high development of the opioid-induced constipation market is credited to the strong government motivation in healthcare sector likewise with the vicinity of an extensive pool of patients suffering from chronic pain
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
-treatment-market-cagr-analysis-by-country.webp "Opioid Induced Constipation (oic) Treatment Market Cagr Analysis By Country")
| Country | CAGR |
|---|---|
| China | 6.2% |
| India | 5.8% |
| Germany | 5.3% |
| France | 4.8% |
| UK | 4.4% |
| USA | 3.9% |
| Brazil | 3.5% |
The Opioid-Induced Constipation (OIC) Treatment Market is expected to register a CAGR of 4.6% during the forecast period, exhibiting varied country level momentum. China leads with the highest CAGR of 6.2%, followed by India at 5.8%. Developed markets such as Germany, France, and the UK continue to expand steadily, while the USA is likely to grow at consistent rates. Brazil posts the lowest CAGR at 3.5%, yet still underscores a broadly positive trajectory for the global Opioid-Induced Constipation (OIC) Treatment Market. In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 5.3%. The USA Opioid-Induced Constipation (OIC) Treatment Market is estimated to be valued at USD 997.0 million in 2025 and is anticipated to reach a valuation of USD 1.5 billion by 2035. Sales are projected to rise at a CAGR of 3.9% over the forecast period between 2025 and 2035. While Japan and South Korea markets are estimated to be valued at USD 147.6 million and USD 87.3 million respectively in 2025.
-treatment-market-analysis-by-company.webp "Opioid Induced Constipation (oic) Treatment Market Analysis By Company")
| Item | Value |
|---|---|
| Quantitative Units | USD 2.9 Billion |
| Active Ingredient | Naloxegol, Lubiprostone, Methylnaltrexone Bromide, Docusate Sodium, and Others (Osmotic laxatives, Emollient or lubricant cathartics, Bulk cathartics, Stimulant cathartics, Prostaglandins or prokinetic drugs) |
| Method of Administration | Oral and Parenteral (Subcutaneous Injection) |
| Drug Class | Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA), Non-selective opioid antagonist, μ-Opioid antagonist, and Locally Acting Chloride Channel Activator (LACCA) |
| Distribution Channel | Hospital Pharmacies, Drug store, and Independent Pharmacies |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
| Country Covered | United States, Canada, Germany, France, United Kingdom, China, Japan, India, Brazil, South Africa |
| Key Companies Profiled | Ironwood Pharmaceuticals (USA), Daiichi Sankyo Co (Japan), Pfizer (USA), Progenics Pharmaceuticals (USA), Shionogi & (Japan), Allergan (Ireland), Nektar Therapeutics (USA), Purdue Pharma (USA), S.L.A. Pharma (Japan), and Mundipharma International Limited (UK) |
The global opioid-induced constipation (oic) treatment market is estimated to be valued at USD 2.9 billion in 2025.
The market size for the opioid-induced constipation (oic) treatment market is projected to reach USD 4.5 billion by 2035.
The opioid-induced constipation (oic) treatment market is expected to grow at a 4.6% CAGR between 2025 and 2035.
The key product types in opioid-induced constipation (oic) treatment market are naloxegol, lubiprostone, methylnaltrexone bromide, docusate sodium and others (osmotic laxatives, emollient or lubricant cathartics, bulk cathartics, stimulant cathartics, prostaglandins or prokinetic drugs).
In terms of method of administration, oral segment to command 61.3% share in the opioid-induced constipation (oic) treatment market in 2025.
Explore Similar Insights
Opioid-Induced Constipation (OIC) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
Chat With
MaRIA
